Kerri A Johannson

List of Publications by Year
in descending order

Version: 2024-02-01

102 papers	3,565 citations	172207 29 h-index	149479 56 g-index
104 all docs	104 docs citations	104 times ranked	2536 citing authors

#	Article	IF	Citations
1	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	1.5	16
2	Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax, 2022, 77, 589-595.	2.7	21
3	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467.	2.5	25
4	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.4	25
5	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 962-970.	1.5	5
6	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	1.3	3
7	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
8	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571.	3.1	57
9	Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respiratory Medicine, 2022, 195, 106792.	1.3	5
10	Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis. Thorax, 2022, 77, 1237-1242.	2.7	14
11	Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1594-1597.	0.4	4
12	Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 863-867.	1.5	2
13	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	1.3	12
14	Perceptions of Genetic Testing: A Mixed-Methods Study of Patients with Pulmonary Fibrosis and Their First-Degree Relatives. Annals of the American Thoracic Society, 2022, 19, 1305-1312.	1.5	2
15	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
16	Environmental and occupational exposures in interstitial lung disease. Current Opinion in Pulmonary Medicine, 2022, 28, 414-420.	1.2	4
17	Clinical characterization of patients with interstitial lung disease: Report from a single Canadian Center. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 310-315.	0.2	0
18	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax, 2021, 76, 37-43.	2.7	28

#	Article	IF	Citations
19	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society, 2021, 18, 1661-1668.	1.5	4
20	Reply: BAL lymphocyte percentage is as good as the company it keeps. European Respiratory Journal, 2021, 57, 2100092.	3.1	0
21	Description of a Multi-faceted COVID-19 Pandemic Physician Workforce Plan at a Multi-site Academic Health System. Journal of General Internal Medicine, 2021, 36, 1310-1318.	1.3	5
22	Antacid Therapy in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 475-476.	0.4	0
23	Pleuroparenchymal Fibroelastosis after Liver Transplantation. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 222-223.	2.5	6
24	Birds of a Feather Precipitate Together. Archivos De Bronconeumologia, 2021, , .	0.4	0
25	Social Media Content of Idiopathic Pulmonary Fibrosis Groups and Pages on Facebook: Cross-sectional Analysis. JMIR Public Health and Surveillance, 2021, 7, e24199.	1.2	7
26	Looking Ahead. Clinics in Chest Medicine, 2021, 42, 375-384.	0.8	2
27	Management of Fibrotic Hypersensitivity Pneumonitis. Clinics in Chest Medicine, 2021, 42, 311-319.	0.8	3
28	Progress and Innovation in Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, xiii-xiv.	0.8	0
29	Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Research, 2021, 7, 00405-2021.	1.1	14
30	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	1.4	5
31	Comparing the Performance of Two Recommended Criteria for Establishing a Diagnosis for Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 865-868.	2.5	9
32	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. Chest, 2021, 160, e97-e156.	0.4	104
33	Exposures and associations with clinical phenotypes in hypersensitivity pneumonitis: A scoping review. Respiratory Medicine, 2021, 184, 106444.	1.3	19
34	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest, 2021, 160, 994-1005.	0.4	20
35	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	6.3	47
36	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal, 2021, 58, 2001518.	3.1	30

#	Article	IF	Citations
37	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	3.1	2
38	Sex and gender in interstitial lung diseases. European Respiratory Review, 2021, 30, 210105.	3.0	19
39	Reply to: Pleuroparenchymal Fibroelastosis Induced by Liver Transplantation?. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
40	Transbronchial lung cryobiopsy in ILD: the data we've been waiting for. Lancet Respiratory Medicine,the, 2020, 8, 129-130.	5.2	1
41	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respiratory Research, 2020, 21, 12.	1.4	29
42	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.2	3
43	Exposure Assessment Tools for Hypersensitivity Pneumonitis. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2020, 17, 1501-1509.	1.5	45
44	Oxygen for interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2020, 26, 464-469.	1.2	7
45	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
46	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 226-228.	0.2	2
47	Occupational exposures and IPF: when the dust unsettles. Thorax, 2020, 75, 828-829.	2.7	3
48	From the 10,000-foot View, We Need Ground-Level Data on Air Pollution and Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 446-448.	0.4	2
49	Gender equity in interstitial lung disease. Lancet Respiratory Medicine,the, 2020, 8, 842-843.	5.2	6
50	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	1.4	18
51	Update in Interstitial Lung Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507.	2.5	17
52	Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-enabled Spirometer Is. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 316-317.	2.5	7
53	Air Pollution and Interstitial Lung Diseases: Defining Epigenomic Effects. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1217-1224.	2.5	16
54	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	1.5	5

#	Article	IF	Citations
55	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax, 2020, 75, 407-412.	2.7	30
56	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
57	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.4	57
58	Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis. European Respiratory Journal, 2020, 56, 2000206.	3.1	58
59	Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 1327-1329.	1.5	26
60	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
61	Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 941-942.	2.5	3
62	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.4	14
63	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 153, 85-90.	1.3	7
64	Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. European Respiratory Journal, 2019, 54, 1900421.	3.1	33
65	Update in the diagnostic approach to fibrotic interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 155-159.	0.2	0
66	YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 572-579.	1.5	82
67	Air Pollution Exposure Is Associated With Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 119-125.	0.4	76
68	Impact of processing technique on bronchoalveolar lavage cellular analysis. European Respiratory Journal, 2018, 51, 1701769.	3.1	1
69	Air pollution exposure and IPF: prevention when there is no cure. Thorax, 2018, 73, 103-104.	2.7	12
70	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
71	Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. Respirology, 2018, 23, 392-398.	1.3	63
72	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.2	8

#	Article	IF	Citations
73	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.2	0
74	Response. Chest, 2018, 154, 727-728.	0.4	0
75	That's a WRAP: laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2018, 6, 655-657.	5.2	0
76	Contralateral recurrence of inflammatory myofibroblastic tumour of the lung 10 years after pneumonectomy. Thorax, 2018, 73, 1089-1090.	2.7	0
77	Pathologic Findings and Prognosis in a LargeÂProspective Cohort of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 152, 502-509.	0.4	131
78	The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax, 2017, 72, 424-429.	2.7	103
79	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
80	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
81	Oxygen Prescription in Interstitial Lung Disease: 2.5 Billion Years in the Making. Annals of the American Thoracic Society, 2017, 14, 1755-1756.	1.5	4
82	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society, 2017, 14, 1373-1377.	1.5	30
83	Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1602406.	3.1	66
84	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
85	Validity of administrative data for identification of obstructive sleep apnea. Journal of Sleep Research, 2017, 26, 132-138.	1.7	22
86	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 151, 619-625.	0.4	177
87	Hot tub lung: A tale of two manifestations. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 67-70.	0.2	0
88	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.2	15
89	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	45
90	A diagnostic model for chronic hypersensitivity pneumonitis. Thorax, 2016, 71, 951-954.	2.7	70

#	Article	IF	Citations
91	Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease: A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2016, 13, 1828-1838.	1.5	158
92	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	1.5	37
93	Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis. , 2016, , .		1
94	Air Pollution Exposure. Chest, 2015, 147, 1161-1167.	0.4	85
95	Models of disease behavior in idiopathic pulmonary fibrosis. BMC Medicine, 2015, 13, 165.	2.3	8
96	Making an Accurate Diagnosis of Chronic Hypersensitivity Pneumonitis. Canadian Respiratory Journal, 2014, 21, 370-372.	0.8	13
97	Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. European Respiratory Journal, 2014, 43, 1124-1131.	3.1	217
98	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT. Lancet Respiratory Medicine,the, 2014, 2, e5.	5.2	8
99	Acute exacerbation of idiopathic pulmonary fibrosis: a proposal. Current Respiratory Care Reports, 2013, 2, 233-240.	0.6	37
100	Clinical relevance of rheumatoid factor and antiâ€citrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , .	1.3	4
101	Genetic testing in interstitial lung disease: An international survey. Respirology, 0, , .	1.3	10
102	The Long-Term Respiratory Perils of War. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	1